Bli medlem
Bli medlem

Du är här



Global Bioenergies secures a line of equity financing

with Société Générale

Evry, 5 October 2015
- Global Bioenergies (Alternext Paris: ALGBE/eligible for PEA-PME) announces
the implementation of an optional line of equity financing (PACEO
®) with Société Générale.

At the current share price[1], the utilisation in full of this line of
financing would procure for the Company an additional funding of 9 million

Subject to certain conditions, most notably the Company's right to suspend
execution of the program at any time, Société Générale has committed to
subscribing 250,000 new shares during the course of the next 36 months, or
8.9% of the current capital. In case of full utilisation of the line[2], a
shareholder holding 1% of the capital would see his equity investment go to
0.92% of the capital[3].

For each tranche, the issue price will include a discount of 5% relative to
the average weighted price by volume of the preceding stock exchange session.
This discount makes it possible for Société Générale, which does not intend
to retain its stake in the Company, to guarantee the subscription of the
shares despite possible volatility of the financial markets.

At the same time, the equity line agreement entered into with Yorkville
Advisors on 16 May 2014 is terminated and the 97,736 share issuance warrants
related to this agreement and not exercised to date are invalid.

François-Henri Sahakian, Global Bioenergies' CFO, states:"Global Bioenergies
has good financial visibility: the gross cash of the Group was 13.8 million
euros at 30 June 2015 (audited), and
14.1 million euros at 30 September 2015 (not audited). We can also count on 5
million euros in subsidies remaining to be received from the BMBF (German
Federal Ministry of Research) and
1.7 million euros from the French State (Investment for the Future). The line
of financing obtained from Société Générale reinforces the financial
situation of Global Bioenergies for the medium term."

Marc Delcourt, CEO of Global Bioenergies, concludes:"Global Bioenergies is
approaching the most value-generating phase of its
history: the startup of the demo plant. The construction of the demo plant is
underway, and should be ended in July 2016. The line of financing signed with
Société Générale will bring us the means to start up and operate the demo
plant, prerequisite to exploiting the process on a large scale."


Global Bioenergies is one of the few companies worldwide, and the only one in
Europe, that is developing a process to convert renewable resources into
hydrocarbons through fermentation. The Company initially focused its efforts
on the production of isobutene, one of the most important petrochemical
building blocks that can be converted into fuels, plastics, organic glass and
elastomers. Global Bioenergies continues to improve the performances of its
process, operates its industrial pilot, has begun the construction of its
demo plant in Germany, and prepares the first full-scale plant through a
Joint-Venture with Cristal Union, named IBN-One. The company also replicated
its achievement to propylene and butadiene, two members of the gaseous
olefins family, key molecules at the heart of petrochemical industry. Global
Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 - ALGBE).

Should you like to be kept informed, subscribe to our news feed on

Follow us on Twitter:


An equity financing solution created by Société Générale, PACEO makes it
possible for issuers to diversify their sources of financing while
contributing additional flexibility, all while optimising the balance sheet
structure. Available by successive drawdowns in exchange for the issuance of
new shares at a price correlated to the market price of the moment, PACEO
procures the same economic and financial benefits as a capital increase, all
while offering the same guarantee as a confirmed line of credit. Société
Générale, leader of equity line operations in France, is putting into place
with this transaction its 51st PACEO®


| |
|François-Henri SAHAKIAN Frédéric SUTTERLIN |
|Chief Financial Officer Associate Director |
|Phone: +33 1 64 98 20 50 Tel.:+33 (0)1 42 13 59 14 |
| |

---------------------------------------[1]€36.14 at the closing price of 01/10/2015
[2]Entailing the issuance of 250,000 new shares
[3]On the basis of 2,800,197 shares making up the capital of Global

Press Release


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GLOBAL BIOENERGIES via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.